Skip to main content

Stopping
Neurodegeneration
at its Source

Mission

At Galimedix, we are working to improve the lives of millions of patients worldwide by developing game-changing drugs to treat major neurodegenerative diseases where amyloid beta plays a role and where better treatments are urgently needed, including dry AMD, glaucoma and Alzheimer’s disease, our initial areas of focus.

Explore

Galimedix’s approach is to block a key step in the neurodegenerative process with a highly specific and well tolerated compound without impacting normal neuronal function

Treating Neurodegeneration of the Eye and Brain

We are currently developing two small molecules with a unique mechanism of action that allows us to tackle the root cause of and alter the course of disease. GAL-101, Galimedix’s lead clinical candidate is a Phase 2 treatment for dry age-related macular degeneration (dry AMD) and glaucoma. GAL-201 is in pre-clinical testing for Alzheimer’s disease.

Our products

Designed to be patient friendly

Our product candidates can be delivered via convenient administration routes – as eye drops or orally – easy for the patient and caregiver and less burdensome to the healthcare system. More importantly, they are designed to be well tolerated with fewer side effects than current treatment options.

Our team

Meet the people behind our pioneering science

News

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101

June 10, 2024
Our Science

Learn more about our novel approach.

We are developing potentially disruptive technology with a unique mechanism of action that enables us to tackle major neurodegenerative diseases at the root.